Arix Bioscience: 32% IRR since inception in 2016
Arix Bioscience: Artios attracts Merck KGaA in deal up to $7bn
Arix Bioscience: Hitting the jackpot
Arix Bioscience Analyst Q&A: Investment team very focused and motivated (LON:ARIX)
Arix Bioscience a diversified portfolio and an IRR of 20% since inception (Analyst Interview)
Arix Bioscience: Realising the valuation disconnect
Arix Bioscience 1Q’20 portfolio update
Arix Bioscience Resetting the stage
Arix Bioscience Fiscal 2019 – moving with the times
Arix Bioscience Analyst Q&A with Dr Dorothea Hill (LON:ARIX)
Arix Bioscience: Multiple inflection points in 2020 (Interview)
Arix Bioscience With high risk can come high reward